GO:0019677 NAD+ catabolic process: NAD+ Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019677 (NAD+ catabolic process) describes the biochemical breakdown of nicotinamide adenine dinucleotide (NAD+), a central redox coenzyme and signaling molecule.
• NAD+ catabolism is mediated by multiple enzyme families including CD38, CD157, SARM1, PARPs, and NMNAT-dependent pathways, and is tightly coupled to NAD+ biosynthesis to maintain cellular NAD+ homeostasis.
• Declining NAD+ catabolic and biosynthetic balance is a hallmark of aging and contributes to metabolic, neurodegenerative, and kidney diseases.
• In cancer, including acute myeloid leukemia, altered NAD+ catabolism supports proliferation and survival, making it a therapeutic target.
• NAD+ catabolic enzymes such as CD38 and SARM1 are being pursued as drug targets for inflammation, neurodegeneration, and metabolic disorders.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential tools to dissect the causal roles of NAD+ catabolic genes in disease.
Description
NAD+ catabolic process (GO:0019677) is defined as the chemical reactions and pathways resulting in the breakdown of nicotinamide adenine dinucleotide (NAD+), a coenzyme that interconverts with its reduced form, NADH, in many redox and catabolic reactions. NAD+ is a central metabolite that serves as an electron carrier in oxidative phosphorylation and as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. The balance between NAD+ biosynthesis and catabolism determines cellular NAD+ levels, which in turn regulate energy metabolism, DNA repair, and stress responses. Dysregulation of NAD+ catabolic process has been implicated in a wide range of human diseases, including acute and chronic kidney diseases, neurodegeneration, and acute myeloid leukemia. For example, increased NAD+ catabolism by CD38 or SARM1 can deplete NAD+ and impair mitochondrial function, contributing to disease progression. Conversely, inhibiting NAD+ catabolic enzymes has shown therapeutic potential in preclinical models. For researchers, understanding GO:0019677 is essential to design experiments that distinguish between NAD+ biosynthesis and catabolism, and to identify which catabolic enzymes are causally involved in a given phenotype. This article provides a research-grade overview of the NAD+ catabolic process, its key genes, regulatory mechanisms, disease links, and the CRISPR-based models and methods used to study it.
NAD+ catabolic process At A Glance
| GO ID | GO:0019677 |
|---|---|
| GO term | NAD+ catabolic process |
| Ontology | biological_process |
| Synonym | NAD breakdown; NAD catabolic process; NAD catabolism; NAD degradation; NADH catabolic process; NADH catabolism; NAD (oxidized) catabolic process; NAD (reduced) catabolic process; nicotinamide adenine dinucleotide catabolic process; oxidized NAD catabolic process; reduced NAD catabolic process |
| Major function | Breakdown of NAD+ and NADH to regulate cellular NAD+ levels, redox balance, and signaling |
| Key enzymes | CD38, CD157, SARM1, PARP1, PARP2, NMNAT, and others |
| Cellular location | Cytosol, nucleus, mitochondria, and extracellular space depending on the enzyme |
| Related pathways | NAD+ biosynthesis, sirtuin signaling, DNA repair, calcium signaling |
| Disease relevance | Aging, kidney disease, neurodegeneration, cancer, metabolic disorders |
What Is GO:0019677?
NAD+ catabolic process (GO:0019677) refers to the set of biochemical reactions that break down nicotinamide adenine dinucleotide (NAD+) into its constituent parts or derived metabolites, such as nicotinamide, ADP-ribose, and cyclic ADP-ribose. This process is distinct from NAD+ biosynthesis and is carried out by enzymes including CD38, CD157, SARM1, and poly(ADP-ribose) polymerases (PARPs). The term encompasses both the degradation of oxidized NAD+ and reduced NADH, as reflected in its synonyms.
Why Is NAD+ catabolic process Important in Cell Biology?
NAD+ catabolic process is critically important because it controls the availability of NAD+ for essential cellular functions, including oxidative phosphorylation, DNA repair, and sirtuin-mediated deacetylation. An imbalance between NAD+ synthesis and catabolism leads to NAD+ depletion, which is a hallmark of aging and multiple diseases. Targeting NAD+ catabolic enzymes has emerged as a promising therapeutic strategy for conditions such as acute kidney injury, neurodegeneration, and leukemia.
• Regulates cellular NAD+ levels, which are essential for energy metabolism and mitochondrial function.
• Controls sirtuin and PARP activities, impacting DNA repair, gene expression, and stress responses.
• Dysregulation contributes to aging and age-related diseases such as neurodegeneration and metabolic syndrome.
• Involved in acute and chronic kidney diseases through NAD+ depletion and oxidative stress.
• Plays a role in cancer biology, including acute myeloid leukemia, by supporting proliferation and survival.
• Provides drug targets such as CD38 and SARM1 for therapeutic intervention.
• NAD+ catabolism influences immune cell function and inflammation.
• Understanding catabolic pathways is necessary for interpreting NAD+ precursor supplementation studies.
• Enables development of biomarkers for NAD+-related diseases.
• Guides CRISPR-based functional genomics screens for NAD+ metabolism genes.
What Happens During NAD+ catabolic process?
Enzymatic cleavage of NAD+ by CD38 and CD157
In simple terms: CD38 and CD157 are enzymes that cut NAD+ into smaller molecules, which can be used for signaling.
CD38 and its homolog CD157 are ectoenzymes that catalyze the hydrolysis of NAD+ to ADP-ribose and nicotinamide, and also produce cyclic ADP-ribose, a calcium signaling molecule. These enzymes are major consumers of NAD+ in mammalian tissues, and their activity increases with age and inflammation. Genetic or pharmacological inhibition of CD38 elevates NAD+ levels and improves metabolic function in preclinical models.
SARM1-mediated NAD+ degradation in axons
In simple terms: SARM1 is an enzyme that destroys NAD+ in injured nerves, leading to axon degeneration.
SARM1 is a TIR-domain protein that, upon activation, exhibits NAD+ glycohydrolase activity and rapidly depletes NAD+ in axons, triggering Wallerian degeneration. This catabolic process is a key driver of neurodegeneration after injury or in disease, and SARM1 inhibitors are being developed as neuroprotective agents.
PARP-mediated NAD+ consumption during DNA repair
In simple terms: PARP enzymes use NAD+ to tag proteins for DNA repair, but overactivation can drain NAD+.
Poly(ADP-ribose) polymerases (PARPs), especially PARP1 and PARP2, consume NAD+ to synthesize poly(ADP-ribose) chains on target proteins during DNA damage response. Excessive PARP activation under oxidative stress can lead to NAD+ depletion and cell death, a process implicated in acute kidney injury and neurodegeneration. Inhibiting PARP activity preserves NAD+ and has therapeutic potential.
NMNAT and the salvage of NAD+ catabolites
In simple terms: NMNAT recycles the breakdown products of NAD+ back into NAD+.
Nicotinamide mononucleotide adenylyltransferases (NMNAT1-3) catalyze the final step of NAD+ biosynthesis by converting NMN to NAD+, thereby counterbalancing catabolic processes. NMNAT2 is particularly important in axons, where its loss leads to SARM1-dependent NAD+ depletion and degeneration. The interplay between NMNAT and catabolic enzymes determines axonal survival.
Regulation of NAD+ catabolism by cellular stress
In simple terms: Cellular stress can increase or decrease NAD+ breakdown to meet the cell's needs.
NAD+ catabolic flux is dynamically regulated by stress signals, including DNA damage, oxidative stress, and inflammation, which activate PARPs and CD38. Conversely, caloric restriction and exercise can reduce CD38 expression and boost NAD+ levels. This regulation ensures that NAD+ is available for survival and repair processes.
Key Genes Involved in GO:0019677 NAD+ catabolic process
The following genes encode enzymes and regulators directly involved in NAD+ catabolic process (GO:0019677) and are commonly studied in this context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD38 | NAD+ glycohydrolase; major NAD+ consumer | Target for NAD+ elevation and aging research |
| CD157 (BST1) | NAD+ glycohydrolase; produces cyclic ADP-ribose | Role in immune and metabolic regulation |
| SARM1 | NAD+ glycohydrolase; triggers axon degeneration | Neurodegeneration target |
| PARP1 | NAD+-dependent ADP-ribosylation in DNA repair | Cancer and kidney disease research |
| PARP2 | NAD+-dependent ADP-ribosylation | DNA repair and metabolism |
| NMNAT1 | NAD+ biosynthesis; counteracts catabolism | Neuroprotection and retinal degeneration |
| NMNAT2 | Axonal NAD+ synthesis | Axon survival and SARM1 regulation |
| NMNAT3 | Mitochondrial NAD+ synthesis | Mitochondrial metabolism |
| NAMPT | Rate-limiting NAD+ biosynthesis enzyme | NAD+ homeostasis and disease |
| NMRK1 | Nicotinamide riboside kinase; NAD+ salvage | NAD+ precursor metabolism |
| NMRK2 | Nicotinamide riboside kinase; NAD+ salvage | Muscle and metabolic research |
| SIRT1 | NAD+-dependent deacetylase; consumes NAD+ | Aging and metabolism |
| SIRT3 | Mitochondrial NAD+-dependent deacetylase | Mitochondrial function |
| CD38 inhibitors | Pharmacological tools to block NAD+ catabolism | Drug discovery |
| SARM1 inhibitors | Block axonal NAD+ degradation | Neuroprotection |
| PARP inhibitors | Block NAD+ consumption by PARPs | Cancer therapy |
| NADSYN1 | NAD+ biosynthesis from quinolinic acid | NAD+ homeostasis |
How Is NAD+ catabolic process Regulated?
NAD+ catabolic process is regulated at multiple levels. Transcriptionally, CD38 and SARM1 expression can be induced by inflammatory cytokines and stress. Post-translationally, SARM1 activity is controlled by its autoinhibitory N-terminal domain and by NMN levels. PARP activity is regulated by DNA damage and auto-modification. Additionally, the circadian clock and nutrient-sensing pathways such as AMPK and mTOR influence NAD+ catabolic flux. This multilayered regulation ensures that NAD+ levels are maintained within a narrow range to support cellular functions.
NAD+ catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD38 | Aging, metabolic syndrome, kidney disease | CD38 knockout mice; overexpression cell lines |
| SARM1 | Neurodegeneration, axonopathy | SARM1 knockout neurons; point mutation models |
| PARP1 | Cancer, acute kidney injury | PARP1 knockout cells; knock-in of catalytic mutants |
| NMNAT2 | Axonal degeneration | NMNAT2 knockout neurons; SARM1 co-deletion |
| NAMPT | Metabolic disorders, cancer | NAMPT overexpression or knockout models |
NAD+ catabolism in kidney diseases
Acute and chronic kidney diseases are associated with altered NAD+ metabolism, including increased catabolism by CD38 and PARPs. NAD+ depletion exacerbates tubular injury and fibrosis, while supplementation with NAD+ precursors or inhibition of catabolic enzymes is protective in preclinical models. These findings highlight NAD+ catabolic process as a therapeutic target in nephrology.
NAD+ catabolism in neurodegeneration
In neurodegenerative conditions, SARM1-mediated NAD+ degradation is a key executioner of axon degeneration. Elevated CD38 and PARP activity also contribute to NAD+ loss and neuronal death. Strategies to block NAD+ catabolism, such as SARM1 inhibitors, are under investigation for neuroprotection.
NAD+ catabolism in cancer
Cancer cells often exhibit increased NAD+ catabolism to support rapid proliferation and survival. In acute myeloid leukemia, NAD+ metabolism is reprogrammed, and targeting catabolic enzymes such as CD38 or PARPs may offer therapeutic opportunities. Understanding the balance between NAD+ synthesis and catabolism is critical for developing effective treatments.
NAD+ catabolism in aging and metabolic disorders
Aging is characterized by declining NAD+ levels due to increased catabolism and reduced biosynthesis. This imbalance contributes to metabolic dysfunction, including insulin resistance and obesity. Interventions that inhibit NAD+ catabolism, such as CD38 inhibitors, have shown promise in improving metabolic health in animal models.
From NAD+ catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CD38 increase NAD+ levels? | CD38 knockout cell lines or mice |
| Does SARM1 catalytic activity drive axon degeneration? | SARM1 point mutation (catalytic dead) knock-in |
| Can NMNAT2 rescue SARM1-dependent degeneration? | NMNAT2 overexpression in neurons |
| What is the role of PARP1 in DNA repair and NAD+ depletion? | PARP1 knockout and knock-in models |
| Does CD38 inhibition improve metabolic function? | CD38 inhibitor treatment in obese mice |
| How does NAD+ catabolism affect leukemia cell survival? | CRISPR knockout of CD38/PARP in AML cell lines |
How to Study the NAD+ catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NAD+ cycling assay | Total NAD+ and NADH levels | Quantifying NAD+ depletion |
| LC-MS metabolomics | NAD+ and related metabolites | Tracing catabolic flux |
| CRISPR knockout screen | Gene essentiality and NAD+ levels | Identifying catabolic regulators |
| Western blot | Protein expression of CD38, SARM1, PARPs | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization of enzymes | Studying CD38 and SARM1 |
| Seahorse assay | Mitochondrial respiration | Linking NAD+ catabolism to OXPHOS |
| Axon degeneration assay | Axonal integrity | SARM1 and NMNAT2 studies |
| ADP-ribosylation detection | PARP activity | DNA damage response |
Measuring NAD+ levels and catabolic flux
NAD+ and its metabolites can be quantified using enzymatic cycling assays, HPLC, or mass spectrometry. Isotope tracing with labeled NAD+ precursors allows measurement of catabolic flux. These methods are essential to determine whether a gene of interest affects NAD+ catabolism.
Genetic screens and CRISPR libraries
CRISPR knockout libraries targeting NAD+ metabolic genes can identify regulators of NAD+ catabolism. Pooled screens with NAD+ sensors or viability readouts enable discovery of synthetic lethal interactions. Bioinformatics analysis of screen data helps prioritize candidate genes.
Proteomics and interactomics
Affinity purification mass spectrometry can identify protein complexes containing NAD+ catabolic enzymes. Post-translational modifications such as ADP-ribosylation can be mapped by proteomics. These approaches reveal signaling networks downstream of NAD+ catabolism.
Imaging and functional assays
Genetically encoded NAD+ sensors (e.g., Peredox, SoNar) allow real-time imaging of NAD+ dynamics in live cells. Axon degeneration assays and mitochondrial function tests provide functional readouts of NAD+ catabolism. These methods link catabolic activity to cellular phenotypes.
How CRISPR Can Be Used to Study GO:0019677 NAD+ catabolic process
Knockout
CRISPR knockout of NAD+ catabolic genes such as CD38, SARM1, or PARP1 is used to determine their contribution to NAD+ levels and cellular phenotypes. For example, CD38 knockout cells show elevated NAD+ and improved mitochondrial function. Knockout models are also valuable for validating drug targets.
Point Mutation
Point mutations that abolish catalytic activity (e.g., SARM1 catalytic dead) can separate enzymatic function from scaffolding roles. Such models are critical to prove that NAD+ catabolism is the driver of a phenotype. CRISPR prime editing or homology-directed repair can introduce these mutations.
Knock-in
Knock-in of tagged versions of NAD+ catabolic enzymes (e.g., GFP-CD38) allows real-time imaging and interactome studies. Knock-in of disease-associated mutations can model human conditions. These models help dissect spatial and temporal regulation of NAD+ catabolism.
Overexpression
Overexpression of CD38, SARM1, or PARP1 is used to induce NAD+ depletion and study downstream consequences. Conversely, overexpression of NMNAT2 can rescue degeneration. Overexpression models are useful for testing whether increased catabolism is sufficient to drive disease phenotypes.
How EDITGENE Supports NAD+ catabolic process Research
Researchers studying NAD+ catabolic process-related genes often need to determine whether a candidate gene is causally involved in NAD+ regulation, metabolic dysfunction, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for NAD+ catabolic process research.
Frequently Asked Questions About NAD+ catabolic process
What is NAD+ catabolic process (GO:0019677)?
NAD+ catabolic process is the set of biochemical reactions that break down nicotinamide adenine dinucleotide (NAD+) into metabolites such as nicotinamide and ADP-ribose, regulating cellular NAD+ levels.
What genes are involved in NAD+ catabolic process?
Key genes include CD38, CD157, SARM1, PARP1, PARP2, and NMNAT family members, which either degrade NAD+ or recycle its breakdown products.
How is NAD+ catabolism linked to aging?
Increased NAD+ catabolism and reduced biosynthesis lead to NAD+ decline during aging, contributing to metabolic and neurodegenerative diseases.
What diseases are associated with NAD+ catabolic process?
Diseases include acute and chronic kidney diseases, neurodegeneration, cancer (e.g., acute myeloid leukemia), and metabolic disorders.
How can I study NAD+ catabolic process in the lab?
Common methods include NAD+ quantification assays, CRISPR knockout screens, metabolomics, and imaging with genetically encoded NAD+ sensors.
What is the role of CD38 in NAD+ catabolism?
CD38 is a major NAD+ glycohydrolase that consumes NAD+ and produces signaling molecules; its inhibition elevates NAD+ levels.
What is SARM1 and how does it relate to NAD+ catabolism?
SARM1 is an NAD+ glycohydrolase that triggers axon degeneration by depleting NAD+; it is a target for neuroprotection.
Can CRISPR be used to study NAD+ catabolic genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the roles of NAD+ catabolic enzymes.
What are the therapeutic opportunities in targeting NAD+ catabolism?
Inhibiting CD38, SARM1, or PARPs can preserve NAD+ and has shown benefits in kidney disease, neurodegeneration, and cancer models.
How does NAD+ catabolism affect mitochondrial function?
NAD+ is essential for oxidative phosphorylation; excessive catabolism depletes NAD+ and impairs mitochondrial respiration.
Conclusion
NAD+ catabolic process (GO:0019677) is a fundamental biological process that controls NAD+ availability and influences aging, metabolism, neurodegeneration, kidney disease, and cancer. The interplay between NAD+ biosynthesis and catabolism determines cellular resilience, and targeting catabolic enzymes offers therapeutic potential. CRISPR-based models are indispensable for dissecting the causal roles of genes such as CD38, SARM1, and PARPs in these contexts. Continued research into NAD+ catabolism will likely yield new biomarkers and treatments for NAD+-related diseases.
References
- 1. Li B et al.. 2022. Attenuates of NAD(+) impair BMSC osteogenesis and fracture repair through OXPHOS.. Stem Cell Res Ther 13(1):77 PMID: 35193674
- 2. Morevati M et al.. 2022. Roles of NAD(+) in Acute and Chronic Kidney Diseases.. Int J Mol Sci 24(1) PMID: 36613582
- 3. Somers K et al.. 2026. NAD Metabolism in Acute Myeloid Leukaemia: Biological Rationale and Therapeutic Opportunities.. Nutrients 18(14) PMID: 42514364
- 4. Covarrubias AJ et al.. 2021. NAD(+) metabolism and its roles in cellular processes during ageing.. Nat Rev Mol Cell Biol 22(2):119-141 PMID: 33353981
- 5. Verdin E. 2015. NAD⁺ in aging, metabolism, and neurodegeneration.. Science 350(6265):1208-13 PMID: 26785480
- 6. Katsyuba E et al.. 2020. NAD(+) homeostasis in health and disease.. Nat Metab 2(1):9-31 PMID: 32694684
- 7. Zapata-Pérez R et al.. 2021. NAD(+) homeostasis in human health and disease.. EMBO Mol Med 13(7):e13943 PMID: 34041853
- 8. Migaud ME et al.. 2024. Regulation of and challenges in targeting NAD(+) metabolism.. Nat Rev Mol Cell Biol 25(10):822-840 PMID: 39026037
